RT Journal Article
SR Electronic
T1 Real time monitoring of COVID-19 outbreak using mobility trend data for Tokyo and Osaka, Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.01.20087155
DO 10.1101/2020.05.01.20087155
A1 Kurita, Junko
A1 Sugawara, Tamie
A1 Ohkusa, Yasushi
YR 2020
UL http://medrxiv.org/content/early/2020/06/01/2020.05.01.20087155.abstract
AB Background In Japan, as a countermeasure against the COVID-19 outbreak, voluntary restrictions against going out (VRG) were applied.Object We examined some associations among trip data provided by Apple Inc. and estimated an effective reproduction number R(t) at the city level.Method We regressed R(t) on a polynomial function of daily data from Apple Inc. using the whole period and the sub-period after March 10, until the end of April. We predicted R(t) prospectively using the estimation results obtained in May.Results Estimation results indicate R(t) as 5.22 in Tokyo and 1.62 in Osaka if VRG ceases and mobility reverts to a normal level. The critical level of R(t) <1 was found to be 70.0% in Tokyo and 91.2% in Osaka compared with the normal level.Discussion and Conclusion Results demonstrate that mobility data from Apple Inc. are useful for prediction of R(t). Moreover, a 9–30% point reduction in trips from home was sufficient to maintain R(t)<1.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study has been published. There is therefore no ethical issue related to this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJapan Ministry of Health, Labour and Welfare. Press Releases. (in Japanese) Apple. Mobility trend Data (in Japanese) https://www.mhlw.go.jp/stf/newpage_10723.html https://www.apple.com/covid19/mobility